CEO of Encompass Health (NYSE: EHC) sells 150,000 common shares

Rhea-AI Filing Summary

Encompass Health Corp. President & CEO Mark J. Tarr, who is also a director, reported multiple open-market sales of company common stock on February 11, 2026.

He sold a total of 150,000 shares at weighted-average prices ranging from $107.47 to $113.58 per share, and directly owned 377,070 shares of Encompass Health common stock after these transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tarr Mark J

(Last) (First) (Middle)

9001 LIBERTY PARKWAY

(Street)

BIRMINGHAM AL 35242

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Encompass Health Corp [ EHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Encompass Health Common Stock	02/11/2026		S		16,216	D	$108.03(1)	510,854	D
Encompass Health Common Stock	02/11/2026		S		13,231	D	$108.8(2)	497,623	D
Encompass Health Common Stock	02/11/2026		S		15,584	D	$110.07(3)	482,039	D
Encompass Health Common Stock	02/11/2026		S		10,954	D	$110.92(4)	471,085	D
Encompass Health Common Stock	02/11/2026		S		6,057	D	$111.89(5)	465,028	D
Encompass Health Common Stock	02/11/2026		S		87,745	D	$113.09(6)	377,283	D
Encompass Health Common Stock	02/11/2026		S		213	D	$113.58	377,070	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.47 to $108.45, inclusive. The reporting pers on undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

2. This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.47 to $109.17, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

3. This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.52 to $110.51, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

4. This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.52 to $111.51, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

5. This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.55 to $112.53, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

6. This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.58 to $113.52, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.

	/s/ Patrick Darby, attorney-in-fact for Mark J. Tarr	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Encompass Health (EHC) Form 4 filed for Mark J. Tarr show?

The Form 4 shows that Mark J. Tarr, President, CEO, and director of Encompass Health, executed multiple open-market sales of the company’s common stock on February 11, 2026, and reports his updated directly held share balance afterward.

How many Encompass Health (EHC) shares did CEO Mark J. Tarr sell?

Mark J. Tarr sold a combined 150,000 shares of Encompass Health common stock in several separate open-market transactions on February 11, 2026, as detailed across multiple line items in Table I of the Form 4 filing.

At what prices were the Encompass Health (EHC) shares sold by the CEO?

The reported sales occurred at weighted-average prices between $107.47 and $113.58 per share. Each price line reflects multiple trades within a disclosed range, with the Form 4 noting that full breakdowns by exact price are available upon request.

How many Encompass Health (EHC) shares does Mark J. Tarr own after these sales?

After the reported transactions, Mark J. Tarr directly owned 377,070 shares of Encompass Health common stock. This figure is disclosed in the “Amount of Securities Beneficially Owned Following Reported Transaction(s)” column for the final line item in Table I.

Were the Encompass Health (EHC) CEO’s share transactions open-market sales?

Yes. Each transaction is coded “S” and described as a sale in open market or private transaction. The Form 4 characterizes these as open-market sales of Encompass Health common stock rather than option exercises or derivative security transactions.

Does the Encompass Health (EHC) Form 4 involve any derivative securities?

No derivative securities are reported. Table II in the filing contains no entries, indicating that these disclosures relate solely to non-derivative Encompass Health common stock rather than options, warrants, or other derivative instruments.